Historical Valuation
Oncology Institute Inc (TOI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.61 is considered Fairly compared with the five-year average of -6.36. The fair price of Oncology Institute Inc (TOI) is between 2.52 to 4.84 according to relative valuation methord.
Relative Value
Fair Zone
2.52-4.84
Current Price：4.31
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Oncology Institute Inc (TOI) has a current Price-to-Book (P/B) ratio of -29.17. Compared to its 3-year average P/B ratio of -0.25 , the current P/B ratio is approximately 11380.93% higher. Relative to its 5-year average P/B ratio of 0.56, the current P/B ratio is about -5322.12% higher. Oncology Institute Inc (TOI) has a Forward Free Cash Flow (FCF) yield of approximately -7.62%. Compared to its 3-year average FCF yield of -82.75%, the current FCF yield is approximately -90.79% lower. Relative to its 5-year average FCF yield of -64.97% , the current FCF yield is about -88.26% lower.
P/B
Median3y
-0.25
Median5y
0.56
FCF Yield
Median3y
-82.75
Median5y
-64.97
Competitors Valuation Multiple
AI Analysis for TOI
The average P/S ratio for TOI competitors is 0.66, providing a benchmark for relative valuation. Oncology Institute Inc Corp (TOI.O) exhibits a P/S ratio of 0.61, which is -8.07% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.
Performance Decomposition
AI Analysis for TOI
1Y
3Y
5Y
Market capitalization of TOI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TOI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TOI currently overvalued or undervalued?
Oncology Institute Inc (TOI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.61 is considered Fairly compared with the five-year average of -6.36. The fair price of Oncology Institute Inc (TOI) is between 2.52 to 4.84 according to relative valuation methord.
What is Oncology Institute Inc (TOI) fair value?
TOI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Oncology Institute Inc (TOI) is between 2.52 to 4.84 according to relative valuation methord.
How does TOI's valuation metrics compare to the industry average?
The average P/S ratio for TOI's competitors is 0.66, providing a benchmark for relative valuation. Oncology Institute Inc Corp (TOI) exhibits a P/S ratio of 0.61, which is -8.07% above the industry average. Given its robust revenue growth of 36.70%, this premium appears sustainable.
What is the current P/B ratio for Oncology Institute Inc (TOI) as of Jan 09 2026?
As of Jan 09 2026, Oncology Institute Inc (TOI) has a P/B ratio of -29.17. This indicates that the market values TOI at -29.17 times its book value.
What is the current FCF Yield for Oncology Institute Inc (TOI) as of Jan 09 2026?
As of Jan 09 2026, Oncology Institute Inc (TOI) has a FCF Yield of -7.62%. This means that for every dollar of Oncology Institute Inc’s market capitalization, the company generates -7.62 cents in free cash flow.
What is the current Forward P/E ratio for Oncology Institute Inc (TOI) as of Jan 09 2026?
As of Jan 09 2026, Oncology Institute Inc (TOI) has a Forward P/E ratio of -10.49. This means the market is willing to pay $-10.49 for every dollar of Oncology Institute Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Oncology Institute Inc (TOI) as of Jan 09 2026?
As of Jan 09 2026, Oncology Institute Inc (TOI) has a Forward P/S ratio of 0.61. This means the market is valuing TOI at $0.61 for every dollar of expected revenue over the next 12 months.